A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain
Phase of Trial: Phase III
Latest Information Update: 08 Mar 2018
At a glance
- Drugs Elagolix (Primary) ; Estradiol/norethisterone
- Indications Endometriosis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 28 Feb 2018 Planned End Date changed from 21 Mar 2021 to 24 May 2021.
- 07 Aug 2017 Planned End Date changed from 24 Mar 2021 to 21 Mar 2021.
- 15 Jul 2017 New trial record